No Data
No Data
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics Announces License of AUCATZYL (Obecabtagene Autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 Years) With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
William Blair Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics: Promising Developments in Lupus Nephritis Drive Buy Rating
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025